Low-molecular-mass secretome profiling identifies C-C motif chemokine 5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma

Journal of Proteomics

Volumn 94, Issue , 2013, Pages 186-201

  Lin, Shih Jie ^a   Chang, Kai Ping ^b   Hsu, Chia Wei ^a   Chi, Lang Ming ^b,c   Chien, Kun Yi ^a,c   Liang, Ying ^c   Tsai, Ming Hung ^a   Lin, Yu Tsun ^a   Yu, Jau Song ^a,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cancer biomarker; Low molecular mass protein; Nasopharyngeal carcinoma; Secretome; Therapeutic target

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; LSM2 PROTEIN; MARAVIROC; NEUTRALIZING ANTIBODY; PROTEIN S 100A2; RANTES; SECRETOME; SUMO 1 PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL MIGRATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; NASOPHARYNX CARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY; UPREGULATION;

10KDA HEAT SHOCK PROTEIN, MITOCHONDRIAL; 1D SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS IN CONJUNCTION WITH NANO-LC-MS/MS; 60S RIBOSOMAL PROTEIN L22; ACTIVATED RNA POLYMERASE II TRANSCRIPTIONAL COACTIVATOR P15; C-C MOTIF CHEMOKINE 5; CANCER BIOMARKER; CCL5; EBV; EPSTEIN-BARR VIRUS; GELC-MS/MS; HSPE1; LMR; LOW-MOLECULAR-MASS; LOW-MOLECULAR-MASS PROTEIN; LSM2; LY6D; LYMPHOCYTE ANTIGEN 6D; MITOCHONDRIAL IMPORT INNER MEMBRANE TRANSLOCASE SUBUNIT TIM13.; NASOPHARYNGEAL CARCINOMA; NPC; RPL22; SECRETOME; SMALL NUCLEAR RIBONUCLEOPROTEIN F; SMALL NUCLEAR RIBONUCLEOPROTEIN SM D1; SMALL UBIQUITIN-RELATED MODIFIER 1; SNRPD1; SNRPF; SUB1; SUMO1; TCEB1; THERAPEUTIC TARGET; TIMM13; TRANSCRIPTION ELONGATION FACTOR B POLYPEPTIDE 1; U6 SNRNA-ASSOCIATED SM-LIKE PROTEIN LSM2;

CELL LINE, TUMOR; CHEMOKINE CCL5; FEMALE; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885898613     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.09.013     Document Type: Article

References (74)

1. Wei W.I., Sham J.S. Nasopharyngeal carcinoma. Lancet 2005, 365:2041-2054.
2. Cheng S.H., Jian J.J., Tsai S.Y., Yen K.L., Chu N.M., Chan K.Y., et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000, 48:1323-1330.
3. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., Wang W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003, 21:631-637.
4. Chang K.P., Hao S.P., Lin S.Y., Ueng S.H., Pai P.C., Tseng C.K., et al. The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope 2006, 116:541-546.
5. Lee A.W., Poon Y.F., Foo W., Law S.C., Cheung F.K., Chan D.K., et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992, 23:261-270.
6. Chang Y.S., Tyan Y.S., Liu S.T., Tsai M.S., Pao C.C. Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol 1990, 28:2398-2402.
7. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol 1992, 3:297-307.
8. Henle G., Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976, 17:1-7.
9. Ho H.C., Ng M.H., Kwan H.C., Chau J.C. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 1976, 34:655-660.
10. Lin J.C., Wang W.Y., Chen K.Y., Wei Y.H., Liang W.M., Jan J.S., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004, 350:2461-2470.
11. Lo Y.M., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999, 59:1188-1191.
12. Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007, 6:1.
13. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
14. Miyake Y., Kodama T., Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994, 54:2136-2140.
15. Chang K.P., Hao S.P., Chang J.H., Wu C.C., Tsang N.M., Lee Y.S., et al. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res 2008, 14:6979-6987.
16. Triantafillidis J.K., Merikas E., Govosdis V., Konstandellou E., Cheracakis P., Barbatzas C., et al. Increased fasting serum levels of growth hormone and gastrin in patients with gastric and large bowel cancer. Hepatogastroenterology 2003, 50(Suppl. 2):cclvi-cclx.
17. Strojan P., Budihna M., Smid L., Svetic B., Vrhovec I., Skrk J. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma 2001, 48:66-71.
18. Tsukishiro S., Suzumori N., Nishikawa H., Arakawa A., Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 2005, 96:516-519.
19. Tirumalai R.S., Chan K.C., Prieto D.A., Issaq H.J., Conrads T.P., Veenstra T.D. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003, 2:1096-1103.
20. Greening D.W., Simpson R.J. A centrifugal ultrafiltration strategy for isolating the low-molecular weight (
21. Bouamrani A., Hu Y., Tasciotti E., Li L., Chiappini C., Liu X., et al. Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics 2010, 10:496-505.
22. Tanaka Y., Akiyama H., Kuroda T., Jung G., Tanahashi K., Sugaya H., et al. A novel approach and protocol for discovering extremely low-abundance proteins in serum. Proteomics 2006, 6:4845-4855.
23. Camerini S., Polci M.L., Liotta L.A., Petricoin E.F., Zhou W. A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood. Proteomics Clin Appl 2007, 1:176-184.
24. Kay R., Barton C., Ratcliffe L., Matharoo-Ball B., Brown P., Roberts J., et al. Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun Mass Spectrom 2008, 22:3255-3260.
25. Capriotti A.L., Caruso G., Cavaliere C., Piovesana S., Samperi R., Lagana A. Comparison of three different enrichment strategies for serum low molecular weight protein identification using shotgun proteomics approach. Anal Chim Acta 2012, 740:58-65.
26. Boschetti E., Righetti P.G. Low-abundance protein discovery: state of the art and protocols 2013, Elsevier Inc., Amsterdam.
27. Volmer M.W., Radacz Y., Hahn S.A., Klein-Scory S., Stuhler K., Zapatka M., et al. Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: landscaping activity of Smad4 as revealed by a "secretome" analysis. Proteomics 2004, 4:1324-1334.
28. Wu C.C., Chien K.Y., Tsang N.M., Chang K.P., Hao S.P., Tsao C.H., et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005, 5:3173-3182.
29. Stastna M., Van Eyk J.E. Secreted proteins as a fundamental source for biomarker discovery. Proteomics 2012, 12:722-735.
30. Pavlou M.P., Diamandis E.P. The cancer cell secretome: a good source for discovering biomarkers?. J Proteomics 2010, 73:1896-1906.
31. Makridakis M., Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteomics 2010, 73:2291-2305.
32. Lescuyer P., Hochstrasser D., Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery?. J Proteome Res 2007, 6:3371-3376.
33. Wu C.C., Hsu C.W., Chen C.D., Yu C.J., Chang K.P., Tai D.I., et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 2010, 9:1100-1117.
34. Schagger H. Tricine-SDS-PAGE. Nat Protoc 2006, 1:16-22.
35. Lin C.T., Chan W.Y., Chen W., Huang H.M., Wu H.C., Hsu M.M., et al. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993, 68:716-727.
36. Lin C.T., Wong C.I., Chan W.Y., Tzung K.W., Ho J.K., Hsu M.M., et al. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest 1990, 62:713-724.
37. Liao S.K., Perng Y.P., Shen Y.C., Chung P.J., Chang Y.S., Wang C.H. Chromosomal abnormalities of a new nasopharyngeal carcinoma cell line (NPC-BM1) derived from a bone marrow metastatic lesion. Cancer Genet Cytogenet 1998, 103:52-58.
38. Nielsen H., Engelbrecht J., Brunak S., von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng 1997, 10:1-6.
39. Petersen T.N., Brunak S., von Heijne G., Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 2011, 8:785-786.
40. Bendtsen J.D., Jensen L.J., Blom N., Von Heijne G., Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 2004, 17:349-356.
41. Moller S., Croning M.D., Apweiler R. Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics 2001, 17:646-653.
42. Bose S., Yap L.F., Fung M., Starzcynski J., Saleh A., Morgan S., et al. The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma. J Pathol 2009, 217:345-352.
43. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Dahl D.B., Chen M., et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res 2006, 66:7999-8006.
44. Dodd L.E., Sengupta S., Chen I.H., den Boon J.A., Cheng Y.J., Westra W., et al. Genes involved in DNA repair and nitrosamine metabolism and those located on chromosome 14q32 are dysregulated in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15:2216-2225.
45. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
46. Cao J., Hu Y., Shen C., Yao J., Wei L., Yang F., et al. Nanozeolite-driven approach for enrichment of secretory proteins in human hepatocellular carcinoma cells. Proteomics 2009, 9:4881-4888.
47. Conesa A., Gotz S., Garcia-Gomez J.M., Terol J., Talon M., Robles M. Blast2GO: a universal tool for annotation, visualization and analysis in functional genomics research. Bioinformatics 2005, 21:3674-3676.
48. Chang K.P., Wu C.C., Chen H.C., Chen S.J., Peng P.H., Tsang N.M., et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics 2010, 10:2644-2660.
49. Chang K.P., Chang Y.T., Wu C.C., Liu Y.L., Chen M.C., Tsang N.M., et al. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 2011, 33:886-897.
50. Tang C.E., Tan T., Li C., Chen Z.C., Ruan L., Wang H.H., et al. Identification of Galectin-1 as a novel biomarker in nasopharyngeal carcinoma by proteomic analysis. Oncol Rep 2010, 24:495-500.
51. Cambien B., Richard-Fiardo P., Karimdjee B.F., Martini V., Ferrua B., Pitard B., et al. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS One 2011, 6:e28842.
52. Long H., Xie R., Xiang T., Zhao Z., Lin S., Liang Z., et al. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 2012, 30:2309-2319.
53. Huang C.Y., Fong Y.C., Lee C.Y., Chen M.Y., Tsai H.C., Hsu H.C., et al. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol 2009, 77:794-803.
54. Chuang J.Y., Yang W.H., Chen H.T., Huang C.Y., Tan T.W., Lin Y.T., et al. CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol 2009, 220:418-426.
55. Charni F., Friand V., Haddad O., Hlawaty H., Martin L., Vassy R., et al. Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. Biochim Biophys Acta 2009, 1790:1314-1326.
56. Vaday G.G., Peehl D.M., Kadam P.A., Lawrence D.M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006, 66:124-134.
57. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732.
58. FDA notifications Maraviroc approved as a CCR5 co-receptor antagonist. AIDS Alert 2007, 22:103.
59. Velasco-Velazquez M., Jiao X., De La Fuente M., Pestell T.G., Ertel A., Lisanti M.P., et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012, 72:3839-3850.
60. Schall T.J., Jongstra J., Dyer B.J., Jorgensen J., Clayberger C., Davis M.M., et al. A human T cell-specific molecule is a member of a new gene family. J Immunol 1988, 141:1018-1025.
61. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
62. Appay V., Rowland-Jones S.L. RANTES: a versatile and controversial chemokine. Trends Immunol 2001, 22:83-87.
63. Luboshits G., Shina S., Kaplan O., Engelberg S., Nass D., Lifshitz-Mercer B., et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999, 59:4681-4687.
64. Borczuk A.C., Papanikolaou N., Toonkel R.L., Sole M., Gorenstein L.A., Ginsburg M.E., et al. Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene 2008, 27:557-564.
65. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008, 267:271-285.
66. Tan M.C., Goedegebuure P.S., Belt B.A., Flaherty B., Sankpal N., Gillanders W.E., et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009, 182:1746-1755.
67. Chang L.Y., Lin Y.C., Mahalingam J., Huang C.T., Chen T.W., Kang C.W., et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 2012, 72:1092-1102.
68. Levy J.A. The unexpected pleiotropic activities of RANTES. J Immunol 2009, 182:3945-3946.
69. Garcia B.A., Smalley D.M., Cho H., Shabanowitz J., Ley K., Hunt D.F. The platelet microparticle proteome. J Proteome Res 2005, 4:1516-1521.
70. Ma Y., Visser L., Roelofsen H., de Vries M., Diepstra A., van Imhoff G., et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008, 111:2339-2346.
71. Makawita S., Smith C., Batruch I., Zheng Y., Ruckert F., Grutzmann R., et al. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics 2011, 10(M111):008599.
72. Tsukishiro S., Suzumori N., Nishikawa H., Arakawa A., Suzumori K. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol 2006, 102:542-545.
73. Niwa Y., Akamatsu H., Niwa H., Sumi H., Ozaki Y., Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001, 7:285-289.
74. Kim H.K., Song K.S., Park Y.S., Kang Y.H., Lee Y.J., Lee K.R., et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003, 39:184-191.